Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
Alessio Gambardella, Gaetano Licata, Anne Sohrt
Dermatology and Therapy (2021) Vol. 11, Iss. 4, pp. 1141-1156
Open Access | Times Cited: 17

Showing 17 citing articles:

Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation
Pedro Herranz, M.L. Alonso‐Pacheco, Rosa Feltes, et al.
Clinical Drug Investigation (2023) Vol. 43, Iss. 7, pp. 517-527
Open Access | Times Cited: 11
Dose escalation of biologic treatment in patients with moderate‐to‐severe psoriasis in Japan
Yayoi Tada, Ahmed M. Soliman, Kanako Ishii, et al.
Experimental Dermatology (2024) Vol. 33, Iss. 5
Closed Access | Times Cited: 3
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review
Giampiero Girolomoni, L. Savage, Paolo Gisondi, et al.
Dermatology and Therapy (2023) Vol. 13, Iss. 10, pp. 2171-2185
Open Access | Times Cited: 7
Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry
Martina Kojanová, Barbora Turková, Spyridon Gkalpakiotis, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3951-3971
Open Access | Times Cited: 2
LTBP2 inhibits prostate cancer progression and metastasis via the PI3K/AKT signaling pathway
Xiaowen Zhang, Chuanjie Tian, Chuanjie Tian, et al.
Experimental and Therapeutic Medicine (2022) Vol. 24, Iss. 3
Open Access | Times Cited: 8
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting
E. Daudén, Elena Escario, Luisa Martos‐Cabrera, et al.
International Journal of Dermatology (2024) Vol. 63, Iss. 4, pp. 503-511
Closed Access | Times Cited: 1
Psoriatic arthritis, biologic therapy experience, body mass index, and onset age of psoriasis were independent factors of secukinumab discontinuation in patients with psoriasis
Neslihan Akdoğan, K. Balan, Başak Yalıcı‐Armağan, et al.
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 8, pp. 755-762
Closed Access | Times Cited: 1
Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis
Rani Soenen, Zhigang Wang, Lynda Grine, et al.
Clinical and Experimental Dermatology (2022) Vol. 47, Iss. 7, pp. 1324-1336
Open Access | Times Cited: 6
Ixekizumab treatment in patients with moderate‐to‐severe plaque psoriasis in a real‐world clinical setting
Neslihan Demirel Öğüt, Sema Koç Yıldırım, Ece Erbağcı, et al.
Journal of Cosmetic Dermatology (2022) Vol. 21, Iss. 11, pp. 6215-6224
Closed Access | Times Cited: 5
Frequency and outcomes of treatment dose escalation with biologics in moderate-to-severe psoriasis: a Swedish register study
Axel Svedbom, Christina Wennerström, Fredrik Hjelm, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access
Dose escalation and associated economic outcomes in patients with psoriasis treated with biologics: A retrospective analysis of German health claims data
Andreas Pinter, Ahmed M. Soliman, Karina C. Manz, et al.
Clinical and Experimental Dermatology (2024) Vol. 49, Iss. 12, pp. 1591-1600
Closed Access
Starting and Maintaining Patients on Biologics and Janus Kinase Inhibitors for Various Immune-mediated Inflammatory Dermatologic Conditions
Clarisse G. Mendoza, C.S. de Jesus, Ma. Corazon Iniego-Rodas
Deleted Journal (2024) Vol. 33, Iss. 2, pp. 47-52
Closed Access
Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States
Jashin J. Wu, Manish Patel, Feng Zeng, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 1
The Cost-Effectiveness of Anti-IL17 Biologic Therapies for Moderate-to-Severe Plaque Psoriasis Treatment in Italy and Germany: A Sequential Treatment Analysis
Nanna Nyholm, Anne Danø, Henrik Schnack, et al.
ClinicoEconomics and Outcomes Research (2023) Vol. Volume 15, pp. 607-619
Open Access | Times Cited: 1
Biological therapy optimization in patients with psoriasis by reducing the dose or increasing the time interval, in a specialized centre in Colombia
Juan Raúl Castro-Ayarza, Mario Barbosa-Rengifo, Manuel Darío Franco-Franco, et al.
Revista Colombiana de Reumatología (2023) Vol. 30, pp. S65-S69
Closed Access
Improving the Accuracy of Biologic Drug Survival Data: The Increasing Prevalence of Off-Label Dosing Must Be Considered when Reporting Drug Effectiveness and Safety
Amaani Hussain, Philip Hampton
Journal of Investigative Dermatology (2023) Vol. 143, Iss. 11, pp. 2096-2098
Open Access
Biological therapy optimization in patients with psoriasis by reducing the dose or increasing the time interval, in a specialized centre in Colombia
Juan Raúl Castro-Ayarza, Mario Barbosa-Rengifo, Manuel Darío Franco-Franco, et al.
Revista Colombiana de Reumatología (English Edition) (2023) Vol. 30, pp. S65-S69
Closed Access
Page 1

Scroll to top